deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04128371

Mepolizumab in Episodic Angioedema With Eosinophilia

Pilot Study of Mepolizumab in Episodic Angioedema With Eosinophilia

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Angioedema Eosinophilia
Interventions mepolizumab
Updated 20 times since 2019 Last updated: Mar 21, 2024 Started: Jan 14, 2021 Primary completion: Oct 31, 2022 Completion: Oct 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was closed after the first five participants completed their participation due to lack of efficacy.

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

Listed as NCT04128371, this PHASE2 trial focuses on Angioedema and Eosinophilia and remains terminated or withdrawn. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 20 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~May 2024 · 17 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  4. Dec 2022 — May 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

▶ Show 15 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  2. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  3. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  4. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  9. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  11. Jun 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  12. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  13. Jan 2021 — Feb 2021 [monthly]

    Suspended PHASE2

  14. Dec 2019 — Jan 2021 [monthly]

    Suspended PHASE2

    Status: Not Yet Recruiting → Suspended

  15. Nov 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations